Imaging Inflammation in Autoimmune Diabetes
Study Details
Study Description
Brief Summary
The purpose of this study is to determine whether magnetic resonance imaging (MRI) with ferumoxtran-10 can be used to detect changes in the pancreas associated with autoimmune diabetes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Approximately one million individuals are afflicted with autoimmune Type 1 diabetes mellitus (T1DM) in the United States. This disease results from the autoimmune destruction of the insulin-producing beta-cells of the islets of Langerhans of the pancreas. Initially, diabetes is usually clinically occult with localized pancreatic inflammation characterized by a lymphocytic infiltration of the pancreatic islets, termed insulitis, which leads to beta-cell specific destruction of the islets. This is often followed by the clinically overt phase that ensues when the bulk of beta cells have been destroyed and the pancreas is no longer able to produce sufficient insulin to maintain glycemic control. The purpose of this study is to assess the ability of magnetic resonance imaging with ferumoxtran-10, a functional molecular imaging agent consisting of iron oxide nanoparticles, to detect changes in the pancreas associated with the insulitis of T1DM.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| 1 Normal controls without evidence of diabetes or islet specific autoimmunity |
|
| 2 Individuals within 6 months of diagnosis with type 1 diabetes |
|
| 3 Individuals at high risk for the development of type 1 diabetes |
|
| 4 Individuals with longstanding autoimmune diabetes |
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
- Recent onset type 1 diabetes as defined by clinical diagnosis within the last 6 months and age less than 30 or at least one islet autoantibody marker (GAD, IAA, or IA-2).
or
- High risk of pre-type 1 diabetes as defined by first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).
or
- Individuals with established type 1 diabetes of greater than 6 months duration who were under age 30 or at least one islet autoantibody marker positive (GAD, IAA, or IA-2) at time of diagnosis or who currently are GAD or IA-2 autoantibody marker positive.
or
- Normal control as defined by no family history of type 1 diabetes and normal tolerance test (tolerance testing to be performed as part of protocol).
Exclusion Criteria:
-
Individuals under 18 years of age
-
Individuals unable or unwilling to give informed consent/HIPAA authorization
-
Individuals who are clinically unstable
-
Individuals with any contraindications to MRI examination, for example, individuals with pacemakers
-
Pregnant or lactating women
-
Individuals with allergies to iron or dextran
-
Individuals with a history of cirrhosis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Joslin Diabetes Center | Boston | Massachusetts | United States | 02215 |
Sponsors and Collaborators
- Joslin Diabetes Center
- Massachusetts General Hospital
- AMAG Pharmaceuticals, Inc.
Investigators
- Principal Investigator: Richard A Jackson, M.D., Joslin Diabetes Center
Study Documents (Full-Text)
None provided.More Information
Publications
- Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12634-9. Epub 2004 Aug 10.
- Turvey SE, Swart E, Denis MC, Mahmood U, Benoist C, Weissleder R, Mathis D. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J Clin Invest. 2005 Sep;115(9):2454-61. Epub 2005 Aug 18.
- Joslin 06-32
- P01-A1-054904